Materialise Makes 3D Printing More Accessible for Radiologists, Surgeons, and Hospitals
November 28, 2017
Partnership with Formlabs creates complete, cost-effective solution for 3D print labs
PLYMOUTH, MICH., Nov. 28, 2017 – Materialise, a leading provider of 3D printing services and software solutions, and Formlabs, a respective leader in the 3D printing industry, are collaborating to deliver a complete, cost-effective and easy-to-use solution for hospitals who are looking to start an in-house 3D print lab. The new offering combines the Materialise Mimics inPrint medical imaging software with Formlabs’ Form 2 printers, the best-selling, professional-grade desktop 3D printers. The proven components of this complete 3D printing package facilitate the implementation of patient-specific solutions at an affordable price-per-print for quick return on investment.
The financial, educational, and clinical benefits of 3D anatomical models for communication and surgical planning have been documented and discussed for years. However, the perceived barriers to developing an onsite 3D print lab, including setup costs and high costs per part, have deterred some hospitals from employing this emerging technology.
“We are committed to removing barriers for 3D printing technology in the medical industry, and this partnership with Formlabs is an important first step in our efforts to expand access to 3D printing in hospitals. Our software is essential to creating virtual and printed 3D models in the medical industry, and with each new partnership, we are bringing greater patient-specific care to more hospitals for a better, healthier world.”
— Brigitte de Vet, Vice President of Medical at Materialise
As the use of 3D anatomical models rapidly progresses in the medical field, it has become a standard procedure and valuable tool for communicating complex surgical plans with patients. Once hospitals have adopted on-site healthcare 3D printing, they are able to easily scale their operations as demand for anatomical models grows.
“Clinicians have seen the value of 3D anatomical models from our Form 2 printer, and they are looking for new ways to bring this innovative technology to their patients. By combining Materialise’s software with Formlabs’ 3D printers, we have developed a simple, easy-to-use solution for hospitals to incorporate 3D printing into their daily practices. Together, we’re introducing technology that enables advancements in precise patient care.”
— Dávid Lakatos, Chief Product Officer at Formlabs
For more information, on this partnership and solution, visit www.materialise.com/en/medical/mimics-inprint-formlabs or stop by the Materialise booth, #7932 in the North - Hall B, during the 2017 Radiological Society of North America’s Annual Meeting at McCormick Place in Chicago from November 26 – December 1.
Materialise incorporates 27 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.
About Materialise’s Medical Division
Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific treatment. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, form the foundation of certified Medical 3D Printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: http://www.materialise.com/en/medical
Formlabs designs and manufactures powerful and accessible 3D printing systems. Headquartered in Boston with offices in Germany, Japan, and China, the company was founded in 2011 by a team of engineers and designers from the MIT Media Lab and Center for Bits and Atoms. Formlabs is establishing the industry benchmark for professional 3D printing for engineers, designers, and manufacturers around the globe, and accelerating innovation in a variety of industries, including education, dentistry, healthcare, jewelry, and research. Formlabs products include the Form 2 SLA 3D printer, Fuse 1 SLS 3D printer, Form Cell manufacturing solution, and Pinshape marketplace of 3D designs. Formlabs also develops its own suite of high-performance materials for 3D printing, as well as best-in-class 3D printing software.
Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.